CANN GROUP LIMITED — Director's Dealing 2018

Apr 12, 2018

==> picture [585 x 60] intentionally omitted <==

ASX ANNOUNCEMENT

13 APRIL 2018

CHANGE OF DIRECTOR’S INTEREST

Please find following a revised Change of Director’s Interest Notice (Appendix 3Y) to correct the Appendix 3Y lodged earlier today.

Cann Group Limited advises that:

1. The revised Appendix 3Y attached is lodged as a result of an internal administrative error. Upon being identified, the ASX was immediately informed and a revised Appendix 3Y has been lodged.

2. Cann Group and its Directors are aware of their obligations under ASX Listing Rule 3.19A. Each director is made aware of this obligation pursuant to their terms of appointment. In addition, Cann Group’s Securities Trading Policy includes the requirement that all Directors must notify the Company Secretary of any dealings in Cann Group’s securities within 2 business days of such dealing occurring.

3. Cann Group’s existing arrangements are considered adequate and the error is an isolated incident. The lodgment of this revised Appendix 3Y provides clarity with regard to the onmarket purchases by the specified Director. Cann Group is aware of its obligations under ASX Listing Rule 3.19A.2. The Directors are also aware of their personal obligations involving Cann Group’s securities.

Richard Baker Company Secretary

Cann Group Limited

For further information please contact: Peter Crock Matthew Wright Cann Group Limited NWR Communications +61 (0) 3 9095 7088 +61 (0) 451 896 420 contact@canngrouplimited.com matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia and internationally (once exports are permitted). The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada’s largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.

==> picture [595 x 78] intentionally omitted <==

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity CANN GROUP LIMITED

ABN 25 603 949 739

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

	Name of Director	GEOFFREY PEARCE	GEOFFREY PEARCE
	Date of last notice	25 JANUARY 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest	EGEA PTY LTD
(including registered holder)	•Director of EGEA Pty Ltd; and
Note: Provide details of the circumstances giving rise to the relevantinterest.	•Shareholder of EGEA Pty Ltd
Date of change	8 February 2018 (100,000 shares) and
	12 April 2018(3,672 shares)
No. of securities held prior to change	1,377,040
Class	FULLY PAID ORDINARY SHARES
Number acquired	100,000 + 3,672 = 103,672
Number disposed	NIL
Value/Consideration	$256,268 + $9,914 = $266,182
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	1,480,712

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change ON-MARKET PURCHASES Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	N/A
If so, was prior written clearance provided to allow thetrade to proceed during this period?	N/A
If prior written clearance was provided, on what date wasthis provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011